Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline


Phase One

Phase One

Therapeutic Approach

Restore CFTR Function

This program is working to advance a gene delivery vehicle that targets cells in the lung. 4D-710 is a customized adeno-associated virus (AAV) vector designed to deliver a healthy CFTR gene specifically to cells in the lungs of people with CF. This would allow the lung cells to create normally functioning CFTR protein, regardless of an individual’s specific CFTR gene mutation.


A Phase 1 study to test the safety of 4D-710 in adults with CF is underway.


This program is sponsored by 4D Molecular Therapeutics and partially funded by the Cystic Fibrosis Foundation.

Contact us about 4D-710 >